#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Treatment of Macular Oedema due to retinal vein occlusion with OZURDEX


Authors: J. Studnička 1;  J. Dusová 1;  J. Skoupá 2;  J. Řehák 3
Authors‘ workplace: Oční klinika FN a LF UK, Hradec Králové přednosta prof. MUDr. Pavel Rozsíval, CSc., FEBO 1;  PHARMA PROJECTS s. r. o., Brno MUDr. Jana Skoupá, MBA 2;  Oční klinika FN a LF UP, Olomouc přednosta prof. MUDr. Jiří Řehák, CSc. FEBO 3
Published in: Čes. a slov. Oftal., 71, 2015, No. 4, p. 199-203
Category: Original Article

Overview

Macular edema due to retinal vein occlusion is the second most common cause of vascular vision impairment. The authors refer two case reports that describe different response to treatment with OZURDEX, biodegradable injectable implant slowly releasing 700 µg dexamethasone. Treatment with corticosteroids is effective also in the case of cystic retinal edema, but its effect can be temporary. The most common adverse events are elevation of intraocular pressure and cataract development.

Key words:
dexamethasone, macular edema, retinal vein occlusion, OZURDEX


Sources

1. Brown, D.M, Campochiaro, P.A., Singh, R.P. et al.: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology, 117, 2010, 6: 1124–33.

2. Campochiaro, P.A., Heier, J.S., Feiner, L. et al.: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology, 117, 2010, 6: 1102–12.

3. Capone, A., Singer, M.A., Dodwell, D.G. et al.: Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA study). Retina, 34, 2014, 2: 342–51.

4. Coscas, G., Augustin, A., Bandello, F. et al.: Retreatment with for Ozurdex macular edema secondary to retinal vein acclusion. Eur J Ophtalmol, 24, 2014, 1: 1–9.

5. Coscas, G., Loewenstein, A., Augustin, A. et al.: Management of retinal vein occlusion--consensus document. Ophthalmologica, 226, 2011, 1: 4–28.

6. Haller, J.A., Bandello, F., Belfort, R. Jr. et al.: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology, 118, 2011, 12: 2453–60.

7. Heier, J.S., Campochiaro, P.A., Yau, L. et al.: Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology, 119, 2012, 4: 802–9.

8. http://www.sukl.cz/modules/medication/detail.php?code=0167756&tab=prices

9. Joshi, L., Yaganti, S., Gemenetzi, M. et al.: Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Brit J Ophthalmol, 97, 2013, 8: 1040–4.

10. Querques, L., Querques, G., Lattanzio, R. et al.: Repeated Intravitreal Dexamethasone Implant (OZURDEX®) for Retinal Vein Occlusion. Ophthalmologica, 229, 2013, 1: 21–25.

11. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macula edema in branch vein occlusion. Am J Ophthalmol, 98, 1984: 271–82.

12. The Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. Arch Ophthalmol, 104, 1986: 34–41.

Labels
Ophthalmology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#